skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Dyslipidemia is an increase or decrease in lipid levels from defined normal parameters and a major modifiable risk factor for cardiovascular disease, one of the world’s leading causes of morbidity and mortality. With a number of key brands used to treat Dyslipidemia facing patent expiration, statin and ezetimibe markets continue to face increasing genericization and the uptake of expensive add-on therapies is expected to spur growth of the Dyslipidemia market. Informa Pharma Intelligence forecasts total antidyslipidemic sales revenues to increase in the US, Japan, and five major EU markets. Datamonitor Healthcare forecasts sales from the US dyslipidemia market as remaining the most lucrative, rising to $22.3bn in 2025. Using the real-time development, pipeline event and impact tracking, and in-depth disease and market landscape reports from Informa Pharma Intelligence products Datamonitor Healthcare and Biomedtracker, this webinar will look at the market dynamics, opportunities, threats from substitutes and payer pressures for marketed drugs, and the likelihood of approval for late-phase pipeline drugs for the Dyslipidemia market. Other points to include in webinar summary:

  • Uptake of expensive add-on therapies is expected to spur growth of the dyslipidemia market.
  • An ability to secure positive CVOT results will play a pivotal role in the reimbursement of PCSK9 inhibitors Repatha and Praluent
  • Reduced cost, favorable dosing regimen, and strong efficacy of inclisiran will result rapid uptake of the medication.
  • The FDC of bempedoic acid and ezetimibe is anticipated to account for the majority of bempedoic acid franchise sales.
  • The statin and ezetimibe markets will continue to face increasing genericization over the forecast period.
  • Datamonitor Healthcare forecasts sales from the US dyslipidemia market will remain the most lucrative and rise to $22.3bn in 2025.

Watch webinar recording


Read also

  • Biomedtracker: follow the drug development process

    Accurate, Intuitive and Updated In Real Time

    03 Apr 2017

    Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.

  • Pink Sheet: global policy and regulatory coverage

    Cancer Immunotherapy: When To Stop Treatment Remains Unanswered Question

    02 Aug 2017

    Long-term or open-ended treatment with PD-1/PD-L1 inhibitors is a burden for patients and the healthcare system and does not fit the biological paradigm of cancer immunotherapies, experts say; however, challenges to studying shorter durations include fears of undertreatment and patient objections to stopping a therapy that appears to be working.

    Topics Clinical trials

  • Scrip: industry news and insights

    Hong Kong Takes On Nasdaq For China Biotech IPOs

    ByBrian Yang

    Hong Kong is catching global attention as it plans to drastically change listing rules for biotech firms, potentially opening the way to both Chinese companies seeking public funding and international firms eyeing entry to China. A Shanghai biosimilars developer, among others, is now eyeing an offering.

    Topics Policy and regulation


Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: